nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.03.2013 | Original article

Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients

A low-field MRI study

verfasst von: M.P. Schmid, MD, B. Mansmann, M. Federico, J.C.A. Dimopoulous, P. Georg, E. Fidarova, W. Dörr, R. Pötter

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Grey zones, which are defined as tissue with intermediate signal intensity in the area of primary hyperintense tumour extension, can be seen during radiation with or without chemotherapy on the T2-weighted MRI in patients with cervical cancer. The purpose of this study was to systematically measure the tumour volume at the time of diagnosis and the residual tumour volume at the time of brachytherapy without and with consideration of the grey zones and to estimate tumour regression during external beam radiotherapy (EBRT).

Material and methods

T2-weighted MRI datasets of 175 patients with locally advanced cervical cancer (FIGO stage IB–IVA), who underwent combined external beam radiotherapy and brachytherapy with or without concomitant chemotherapy were available for this study. The gross tumour volume at the time of diagnosis (GTV_init) and at the time of first brachytherapy without (GTV_res) and with (GTV_res+ GZ) consideration of grey zones were measured for each patient. A descriptive statistical analysis was performed and tumour regression rates without (R) and with consideration of grey zones (R_GZ) were calculated. Further, the role of prognostic factors on GTV_init, GTV_res, GTV_res+ GZ and tumour regression rates was investigated.

Results

The median GTV_init, GTV_res, GTV_res+ GZ in all patients were 44.4 cm³, 8.2 cm³, 20.3 cm³, respectively. The median R was 78.5% and the median R_GZ was 50.1%. The histology and FIGO staging showed a significant impact on GTV_init, GTV_res and GTV_res+ GZ.

Conclusion

Grey zones represent a substantial proportion of the residual tumour volume at the time of brachytherapy. Differentiation of high signal intensity mass and surrounding intermediate signal intensity grey zones may be reasonable.

Nagy V, Coza O, Ordeanu C et al (2009) Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma. Long term results of a phase III randmoized trial. Strahlenther Onkol 185:177–183PubMedCrossRef

Patyánik M, Nemeskéri C, Sinkó D et al (2009) Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin? Strahlenther Onkol 185:582–587PubMedCrossRef

Marnitz S, Stromberger C, Kawgan-Kagan M et al (2010) Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity. Strahlenther Onkol 186:572–579PubMedCrossRef

Heinzelmann F, Henke G, von Grafenstein M et al (2012) Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer. Strahlenther Onkol 188:568–575PubMedCrossRef

Gruen A, Musik T, Köhler C et al (2011) Adjuvant chemoradiation after laparoscopically assisted vaginal radical hysterektomy (LARVH) in patients with cervical cancer: oncologic outcome and morbidity. Strahlenther Onkol 187:344–349PubMedCrossRef

Mayr NA, Taoka T, Yuh WTC et al (2002) Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 52:14–22PubMedCrossRef

Nam H, Park W, Huh SJ et al (2007) The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol 107:320–325PubMedCrossRef

Wang JZ, Mayr NA, Zhang D et al (2010) Sequential magnetic resonance imaging of cervical cancer: the predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy. Cancer 116:5093–5101PubMedCrossRef

Dimopoulos JCA, Schard G, Berger D et al (2006) Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: potential of MRI on delineation of target, pathoanatomic structures, and organs at risk. Int J Radiat Oncol Biol Phys 64:1380–1388PubMedCrossRef

10.

Brocker KA, Alt CD, Eichbaum M et al (2011) Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 1. Strahlenther Onkol 187:611–618PubMedCrossRef

11.

Alt CD, Brocker KA, Eichbaum M et al (2011) Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2. Strahlenther Onkol 187:705–714PubMedCrossRef

12.

Mayr NA, Tali ET, Yuh WT et al (1993) Cervical cancer: application of MR imaging in radiation therapy. Radiology 189:601–608PubMed

13.

Flueckiger F, Ebner F, Poschauko H et al (1992) Cervical cancer: serial MR imaging before and after primary radiation therapy–a 2-year follow-up study. Radiology 184:89–93PubMed

14.

Sironi S, Belloni C, Taccagni G et al (1991) Invasive cervical carcinoma: MR imaging after preoperative chemotherapy. Radiology 180:719–722PubMed

15.

Haie-Meder C, Pötter R, Van Limbergen E et al (2005) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74:235–245PubMedCrossRef

16.

Pötter R, Dimopoulos J, Georg P et al (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83:148–155PubMedCrossRef

17.

Pötter R, Georg P, Dimopulos J et al (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123PubMedCrossRef

18.

Vincens E, Balleyguier C, Rey A et al (2008) Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy. Cancer 113:2158–2164PubMedCrossRef

19.

Allen SD, Padhani AR, Dzik-Jurasz AS, Glynne-Jones R (2007) Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. AJR Am J Roentgenol 188:442–451PubMedCrossRef

20.

Dresen RC, Beets GL, Rutten, HJT et al (2009) Locally advanced rectal cancer: MR Imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy Part I. Are we able to predict tumor confined to the rectal wall? Radiology 252:71–80PubMedCrossRef

21.

Chargari C, Magné N, Dumas I et al (2009) Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Rad Oncol Biol Phys 74:133–139CrossRef

22.

Toita T, Kakinohana Y, Shinzato S et al (1999) Tumor diameter/volume and pelvic node status assessed by magnetic resonance imaging (MRI) for uterine cervical cancer treated with irradiation. Int J Radiat Oncol Biol Phys 43:777–782PubMedCrossRef

23.

Hatano K, Sekiya Y, Araki H et al (1999) Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 45:639–644PubMedCrossRef

24.

Kirisits C, Pötter R, Lang S et al (2005) Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 262:901–911CrossRef

25.

Ohara K, Oki A, Tanaka YO et al (2006) Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors. Int J Radiat Oncol Biol Phys 64:1179–1182PubMedCrossRef

26.

Lim K, Chan P, Dinniwell R et al (2008) Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia. Int J Radiat Oncol Biol Phys 70:126–133PubMedCrossRef

27.

Dimopoulos JCA, Schirl G, Baldinger A et al (2009) MRI assessment of cervical cancer for adaptive radiotherapy. Strahlenther Onkol 185:282–287PubMedCrossRef

28.

Tanderup K, Nielsen SK, Nyvang GB et al (2010) From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organ at risk in brachytherapy of cervical cancer. Radiother Oncol 94(2):173–180PubMedCrossRef

29.

Haie-Meder C, Chargari C, Rey A et al (2010) MRI-based low dose-rate brachytherapy experience in locally advanced cervical cancer patients initially treated by concomitant chemoradiotherapy. Radiother Oncol 96:161–165PubMedCrossRef

30.

Jamema SV, Kirisits C, Mahanshetty U et al (2010) Comparison of DVH parameters and patterns of standard loading, manual and inverse optimization for intracavitary brachytherapy on a subset of tandem/ovoid cases. Radiother Oncol 97:501–506PubMedCrossRef

31.

Mayr NA, Yuh WTC, Taoka T et al (2006) Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol 187:65–72PubMedCrossRef

32.

Barillot I, Horiot JC, Pigneux J et al (1997) Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys 38:969–978PubMedCrossRef

33.

Hong JH, Tsai CS, Wang CC et al (2000) Comparison of clinical behaviors and responses to radiation between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the cervix. Chang Gung Med J 23:396–404PubMed

34.

Dimopoulos JCA, Petrow P, tanderup K et al (2012) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol 103:113–122PubMedCrossRef

35.

Zahra MA, Tan LT, Priest AN et al (2009) Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 74:766–773PubMedCrossRef

36.

Mayr NA, Wang JZ, Zhang D et al (2010) Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int J Radiat Oncol Biol Phys 77:502–508PubMedCrossRef

37.

Mayr NA, Huang Z, Wang JZ et al (2012) Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: Cervical cancer as a model. Int J Radiat Oncol Biol Phys 83:972–979PubMed

Titel: Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients
A low-field MRI study
verfasst von: M.P. Schmid, MD
B. Mansmann
M. Federico
J.C.A. Dimopoulous
P. Georg
E. Fidarova
W. Dörr
R. Pötter
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0260-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients

A low-field MRI study

Abstract

Background

Material and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Material and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Primäre kurative Radiochemotherapie beim Nasopharynxkarzinom

Mitteilungen der Fachgesellschaften

Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?

Dysphagia after definitive radiotherapy for head and neck cancer

Bestrahlungsdosen und Kataraktrate bei Überlebenden der Atombombe

Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie